46 related articles for article (PubMed ID: 21474967)
21. Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Onco Targets Ther; 2017; 10():4989-4995. PubMed ID: 29075129
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.
Singh N; Jindal A; Behera D
World J Clin Oncol; 2014 Dec; 5(5):858-64. PubMed ID: 25493223
[TBL] [Abstract][Full Text] [Related]
23. Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?
Zhao ZR; Li W; Long H
Sci Rep; 2014 Aug; 4():5996. PubMed ID: 25104233
[TBL] [Abstract][Full Text] [Related]
24. Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Jang SH
Tuberc Respir Dis (Seoul); 2014 Jan; 76(1):8-14. PubMed ID: 24523812
[TBL] [Abstract][Full Text] [Related]
25. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Zhao ZR; Wang JF; Lin YB; Wang F; Fu S; Zhang SL; Su XD; Jiang L; Zhang YG; Shao JY; Long H
Med Oncol; 2014 Jan; 31(1):810. PubMed ID: 24338271
[TBL] [Abstract][Full Text] [Related]
26. Drug rechallenge and treatment beyond progression--implications for drug resistance.
Kuczynski EA; Sargent DJ; Grothey A; Kerbel RS
Nat Rev Clin Oncol; 2013 Oct; 10(10):571-87. PubMed ID: 23999218
[TBL] [Abstract][Full Text] [Related]
27. Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.
Song Z; Yu X; He C; Zhang B; Zhang Y
J Thorac Dis; 2013 Aug; 5(4):400-5. PubMed ID: 23991294
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Lee JC; Jang SH; Lee KY; Kim YC
Cancer Res Treat; 2013 Jun; 45(2):79-85. PubMed ID: 23864840
[TBL] [Abstract][Full Text] [Related]
29. The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Otsuka T; Kitai K; Kawase I
Chin J Cancer; 2013 Mar; 32(3):136-40. PubMed ID: 23237215
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Cersosimo RJ
Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Asahina H; Oizumi S; Inoue A; Kinoshita I; Ishida T; Fujita Y; Sukoh N; Harada M; Maemondo M; Saijo Y; Dosaka-Akita H; Isobe H; Nukiwa T; Nishimura M;
Oncology; 2010; 79(5-6):423-9. PubMed ID: 21474967
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
35. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
